Levels Prescription and Intake Process: How It Works, What to Expect

What Levels Actually Is

Levels is a subscription platform that pairs a prescribed continuous glucose monitor with proprietary software to generate a "metabolic score" from real-time interstitial glucose readings. The company does not manufacture its own sensor hardware. It partners with Dexcom and Abbott, whose FDA-cleared devices (Dexcom G7, FreeStyle Libre 3) collect glucose data every 1 to 5 minutes [1].

The clinical premise rests on a growing body of evidence linking glycemic variability to cardiometabolic risk even in non-diabetic populations. A 2023 cohort study in The Lancet Regional Health (N=7,928) found that higher glycemic variability predicted incident type 2 diabetes independently of HbA1c [2]. Levels translates this research into a consumer product by scoring meals, exercise, and sleep against glucose response curves.

The platform is not a diabetes management tool. It markets itself to metabolically healthy or pre-diabetic adults seeking optimization. This distinction matters for the prescription pathway: clinicians reviewing Levels intakes are not managing a diagnosed condition but rather facilitating access to a monitoring device for wellness purposes.

The Intake and Prescription Workflow, Step by Step

The entire prescription process is asynchronous and typically completes within 48 to 72 hours. No synchronous video or phone consultation is required unless a clinician flags a concern during chart review.

Step 1: Account creation and health questionnaire. Users answer approximately 30 questions covering medical history, current medications, diagnosed conditions, allergies, and metabolic goals. The questionnaire screens for contraindications (e.g., active diabetic ketoacidosis, pregnancy in some cases, or conditions requiring direct endocrinology oversight).

Step 2: Clinician review. A licensed physician or nurse practitioner in the user's state reviews the submitted health information. Levels contracts with a distributed network of telehealth providers credentialed across all 50 states. Median review time is under 24 hours based on user-reported data.

Step 3: Prescription issuance. If approved, the clinician issues a prescription for a CGM device. The Rx is sent electronically to Levels' pharmacy partner.

Step 4: Sensor fulfillment. Sensors ship directly to the user, typically arriving within 3 to 7 business days after prescription approval.

Step 5: App onboarding and first scan. Once the sensor is applied (a 30-second painless insertion on the upper arm), the Levels app begins receiving glucose data and calibrating the user's baseline metabolic profile over the first 48 to 72 hours.

Clinical Legitimacy: Is the Prescription Process Sound?

The American Medical Association's 2022 guidance on asynchronous telehealth encounters states that store-and-forward models are appropriate for low-acuity prescribing decisions when adequate patient history is collected [3]. CGM prescriptions for wellness monitoring in non-diabetic adults fit this category.

A legitimate concern: CGMs are FDA-cleared as medical devices, and prescribing them without a synchronous clinical encounter raises questions about thoroughness. The Endocrine Society's 2023 position statement notes that CGM use in non-diabetic populations "may provide actionable glycemic data but lacks long-term outcome evidence for behavior change" [4].

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Continuous glucose monitoring provides granular data that can inform dietary choices, but we need more randomized controlled trials in non-diabetic populations to understand whether this translates to meaningful clinical endpoints" [5].

The prescription itself is straightforward. CGMs carry minimal safety risk. The FreeStyle Libre 3 and Dexcom G7 have well-established safety profiles from large diabetes trials. In the REPLACE trial (N=224), FreeStyle Libre use showed no increase in adverse events compared to standard blood glucose monitoring over 6 months [6]. The clinical question is not safety but rather whether the data generated produces durable metabolic behavior change in healthy users.

What Levels Prescribes (and What It Does Not)

Levels prescribes only CGM sensors. It does not prescribe medications, supplements, or any pharmaceutical intervention. The platform is purely a monitoring-and-coaching layer.

Specifically, users receive:

• Dexcom G7 (14-day wear, 5-minute readings, no fingerstick calibration needed) or
• Abbott FreeStyle Libre 3 (14-day wear, 1-minute readings, factory-calibrated)

Both devices measure interstitial glucose, which lags capillary blood glucose by approximately 5 to 15 minutes [7]. This lag is clinically irrelevant for the pattern-recognition use case Levels targets but is worth noting for users comparing readings against fingerstick meters.

Levels does not prescribe metformin, GLP-1 receptor agonists, or any glucose-lowering medication. Users seeking pharmacologic intervention for insulin resistance or pre-diabetes should pursue a dedicated telehealth or in-person endocrinology consultation.

Cost Breakdown and Subscription Structure

Levels operates on a tiered subscription model:

• Annual membership: approximately $199/month (billed annually at ~$2,388), includes 2 CGM sensors per month plus full app access
• Month-to-month: approximately $399/month, includes sensors and app access without long-term commitment

These prices position Levels at a premium compared to obtaining a CGM prescription independently. A FreeStyle Libre 3 sensor retails at approximately $75 without insurance. Two sensors per month through a retail pharmacy would cost roughly $150, making the Levels markup approximately $50 to $250/month depending on plan, covering the software layer, clinical intake, and data interpretation.

Insurance coverage for CGMs in non-diabetic individuals remains rare. Medicare covers CGMs only for patients on insulin or with documented hypoglycemia risk [8]. Most commercial payers follow similar medical-necessity criteria, making out-of-pocket payment the norm for Levels users.

Levels vs. Alternatives: Comparative Analysis

Several competitors now occupy the CGM-for-wellness space. Key differentiators:

Nutrisense offers a similar CGM subscription ($225-$399/month) but includes access to registered dietitians for 1-on-1 consultation. The intake process also uses asynchronous telehealth prescribing.

Signos pairs CGM data with a weight-loss-focused algorithm and charges $199-$399/month. It requires a brief synchronous telehealth visit for prescriptions in some states.

January AI uses an AI model trained on CGM data to predict glucose responses without requiring continuous sensor wear after an initial calibration period. Pricing runs $288/year after an initial sensor month.

Veri operates primarily in markets where CGMs are available over-the-counter (parts of Europe) and offers US access through a similar telehealth prescription pathway at $199-$299/month.

A 2024 systematic review in Diabetes Technology & Therapeutics examined 12 studies of CGM use in non-diabetic adults (combined N=1,247) and found a mean reduction in time spent above 140 mg/dL of 27 minutes per day, with modest improvements in dietary glycemic index selection [9]. No study reported clinically significant HbA1c reductions in normoglycemic participants, suggesting the benefit is behavioral rather than biomarker-driven.

The differentiator between platforms is primarily software quality and coaching access, not the underlying CGM technology, since all competitors use the same two sensor families.

Does the Data Actually Change Behavior?

This is the central question for any wellness CGM platform. A prospective cohort study published in the Journal of Clinical Endocrinology & Metabolism (2023, N=153 non-diabetic adults wearing CGMs for 28 days) found that 72% of participants reported making at least one sustained dietary modification based on glucose feedback [10]. Self-reported dietary changes persisted at 3-month follow-up in 48% of participants.

A randomized controlled trial at Stanford (2022, N=116) showed that CGM-guided dietary counseling reduced postprandial glucose excursions by 11% compared to standard dietary advice alone over 12 weeks [11]. The effect was most pronounced in participants with baseline fasting glucose between 100 and 125 mg/dL (the pre-diabetic range).

Dr. Michael Snyder, Director of Stanford's Center for Genomics and Personalized Medicine, who led the study, noted: "Individuals in the pre-diabetic range showed the most actionable responses to CGM feedback. For those with completely normal glucose metabolism, the signal-to-noise ratio decreases substantially" [11].

This suggests Levels and similar platforms deliver the most clinical value to users with emerging metabolic dysfunction rather than those already metabolically optimized.

Red Flags and Limitations to Consider

No platform review is complete without addressing shortcomings:

Overinterpretation risk. Normal physiologic glucose variability (postprandial rises to 140-160 mg/dL) can alarm users unfamiliar with glycemic physiology. The International Consensus on Time in Range defines normal as spending less than 5% of time above 180 mg/dL for non-diabetic individuals [12]. Levels' "zone score" penalizes readings above 110 mg/dL, which is stricter than any clinical guideline.

Lack of outcome data. Levels has not published peer-reviewed studies demonstrating that its specific scoring algorithm produces superior metabolic outcomes compared to raw CGM data alone or to competing platforms.

Subscription lock-in. Sensors ship only through the subscription. Users cannot apply the Levels software to independently purchased CGMs, creating vendor dependency.

Regulatory gray zone. The FDA has not evaluated Levels' metabolic scoring algorithm as a medical device. The underlying CGMs are FDA-cleared, but the software interpretation layer operates as a wellness product outside FDA oversight. The FDA's 2023 draft guidance on clinical decision support software would likely classify Levels' algorithm as non-device CDS under 21st Century Cures Act criteria [13], but this classification remains untested.

Who Should (and Should Not) Use Levels

Based on available evidence, the strongest use case for a CGM wellness subscription exists in adults with:

• Fasting glucose 100-125 mg/dL (pre-diabetes range per ADA criteria [14])
• Family history of type 2 diabetes seeking early metabolic insight
• PCOS with suspected insulin resistance
• Post-bariatric patients monitoring glycemic stability

The weakest use case: metabolically healthy adults with fasting glucose below 90 mg/dL and HbA1c below 5.4%. For these individuals, a 2024 analysis in Annals of Internal Medicine (N=5,032) found CGM-detected glycemic patterns showed minimal intra-individual variation day-to-day, limiting the actionable insight available [15].

Levels costs between $2,388 and $4,788 annually. For users in the pre-diabetic range, this investment could be justified against the lifetime cost of type 2 diabetes management (estimated at $16,752 per year in direct medical expenditures per the ADA's 2023 cost analysis [16]). For normoglycemic users, the return on investment is speculative.

Practical Recommendations Before Signing Up

Get a baseline metabolic panel first. A fasting glucose, fasting insulin, HbA1c, and lipid panel (total cost: $50-$150 at most direct-access labs) will tell you whether you fall into the population most likely to benefit from CGM feedback. If your fasting glucose is below 95 mg/dL and HbA1c is below 5.4%, consider whether $199-$399/month delivers sufficient insight beyond what a food diary and standard glucose meter ($30 plus $0.50/strip) would provide.

If you proceed with Levels, commit to a minimum 60-day trial period. The first 14 days establish baseline patterns. The second month is where dietary experiments (testing specific meals, exercise timing, sleep impact) generate personalized data. A single month provides insufficient context for meaningful behavioral conclusions.